PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31352325-8 2019 To investigate whether the activation of inflammasome participates in the liver damage induced by TP, a single dose of Ac-Yvad-Cmk (Caspase-1 inhibitor) was injected before TP administration. ac-yvad 119-126 chemokine (C-X-C motif) ligand 9 Mus musculus 127-130 31352325-9 2019 Ac-Yvad-Cmk pretreatment effectively prevented the increase of Cleaved Caspase-1 and inhibited the maturity of IL-1beta. ac-yvad 0-7 chemokine (C-X-C motif) ligand 9 Mus musculus 8-11 31352325-10 2019 Additional studies revealed that Ac-Yvad-Cmk pretreatment decreased the recruitment of neutrophils and inhibited the production of massive pro-inflammatory factors. ac-yvad 33-40 chemokine (C-X-C motif) ligand 9 Mus musculus 41-44 30897338-5 2019 C57/BL6 mouse pups were randomized to receive daily intraperitoneal injections of Ac-YVAD-CMK, an irreversible caspase-1 inhibitor, or placebo during exposure to room air or hyperoxia (85% O2) for 10 days. ac-yvad 82-89 chemokine (C-X-C motif) ligand 9 Mus musculus 90-93 30473634-12 2018 However, this response was ameliorated by inhibition of the inflammasome with Ac-Tyr-Val-Ala-Asp-Chloromethylketone (Ac-YVAD-CMK). ac-yvad 117-124 chemokine (C-X-C motif) ligand 9 Mus musculus 125-128 30276509-5 2019 We used the NLRP3 inhibitor MCC950 and the caspase-1 inhibitor Ac-YVAD-CMK to study the role of the NLRP3/caspase-1 pathway in pyroptosis and cognitive deficits in a mouse model of SAE. ac-yvad 63-70 chemokine (C-X-C motif) ligand 9 Mus musculus 71-74 30276509-9 2019 In addition, administration of MCC950 or Ac-YVAD-CMK rescues cognitive deficits and ameliorates increased hippocampal NLRP3-mediated neuronal pyroptosis and pro-inflammatory cytokines. ac-yvad 41-48 chemokine (C-X-C motif) ligand 9 Mus musculus 49-52 30410928-0 2018 AC-YVAD-CMK Inhibits Pyroptosis and Improves Functional Outcome after Intracerebral Hemorrhage. ac-yvad 0-7 chemokine (C-X-C motif) ligand 9 Mus musculus 8-11 30410928-5 2018 We tested a well-known selective inhibitor of caspase-1, AC-YVAD-CMK, which has previously been found to have neuroprotective effects in ICH mice model, to ascertain its effects on the activation of inflammasomes mediated pyroptosis. ac-yvad 57-64 chemokine (C-X-C motif) ligand 9 Mus musculus 65-68 30410928-6 2018 Our results showed that AC-YVAD-CMK could reduce caspase-1 activation and inhibit IL-1beta production and maturation, but has no effect on NLRP3 expression, an upstream inflammatory complex. ac-yvad 24-31 chemokine (C-X-C motif) ligand 9 Mus musculus 32-35 30410928-7 2018 AC-YVAD-CMK administration also resulted in reduction in M1-type microglia polarization around the hematoma, while increasing the number of M2-type cells. ac-yvad 0-7 chemokine (C-X-C motif) ligand 9 Mus musculus 8-11 30410928-8 2018 Furthermore, AC-YVAD-CMK treated mice showed some recovery of neurological function after hemorrhage especially at the hyperacute and subacute stage resulting in some degree of limb movement. ac-yvad 13-20 chemokine (C-X-C motif) ligand 9 Mus musculus 21-24 30410928-9 2018 In conclusion, we are of the view that AC-YVAD-CMK could inhibit pyroptosis, decrease the secretion or activation of inflammatory factors, and affect the polarization of microglia resulting in improvement of neurological function after ICH. ac-yvad 39-46 chemokine (C-X-C motif) ligand 9 Mus musculus 47-50 29382416-0 2017 [Caspase-1 inhibitor AC-YVAD-CMK blocks IL-1beta secretion of bone marrow-derived macrophages induced by Acinetobacter baumannii]. ac-yvad 21-28 chemokine (C-X-C motif) ligand 9 Mus musculus 29-32 29382416-1 2017 Objective To explore the effect of caspase-1 selective inhibitor AC-YVAD-CMK on IL-1beta secretion of bone marrow-derived macrophages (BMDMs) induced by Acinetobacter baumannii (A. baumannii). ac-yvad 65-72 chemokine (C-X-C motif) ligand 9 Mus musculus 73-76 29382416-5 2017 The role of caspase-1 in the secretion of IL-1beta was tested by AC-YVAD-CMK treatment to block caspase-1. ac-yvad 65-72 chemokine (C-X-C motif) ligand 9 Mus musculus 73-76 29382416-10 2017 Mature IL-1beta secretion was blocked by AC-YVAD-CMK either in vitro or in vivo. ac-yvad 41-48 chemokine (C-X-C motif) ligand 9 Mus musculus 49-52 29382416-11 2017 The damage of lung induced by A. baumannii infection in mice was ameliorated by AC-YVAD-CMK. ac-yvad 80-87 chemokine (C-X-C motif) ligand 9 Mus musculus 88-91 29382416-12 2017 Conclusion AC-YVAD-CMK alleviates pulmonary pathological damage by reducing the caspase-1-mediated IL-1beta secretion. ac-yvad 11-18 chemokine (C-X-C motif) ligand 9 Mus musculus 19-22 28482444-4 2017 RAW264.7 cells pretreated with various concentrations (0, 5, 10, 25, 50, 75, 100, 200 mumol/L) of AC-YVAD-CMK for 2 h, and stimulated by 1 mg/L Pg LPS for 24 h in the third group. ac-yvad 98-105 chemokine (C-X-C motif) ligand 9 Mus musculus 106-109 28482444-7 2017 Results: It is observed that treatment with 5, 10, 25, 50, 75, 100, 200 mumol/L AC-YVAD-CMK did not significantly affect the viability of RAW264.7 cells. ac-yvad 80-87 chemokine (C-X-C motif) ligand 9 Mus musculus 88-91 28245402-0 2017 [Caspase1 Inhibitor Ac-YVAD-CMK Prevents and Treats the Acute Graft Versus Host Disease in Mice]. ac-yvad 20-27 chemokine (C-X-C motif) ligand 9 Mus musculus 28-31 28245402-1 2017 OBJECTIVE: To explore the effect of Caspase 1 inhibitor Ac-YVAD-CMK on acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation(allo-HSCT) and its mechanism. ac-yvad 56-63 chemokine (C-X-C motif) ligand 9 Mus musculus 64-67 28245402-7 2017 RESULTS: Ac-YVAD-CMK could alleviate murine aGVHD and pathological injury, decreare the incidence and severity of aGVHD in recipient mice. ac-yvad 9-16 chemokine (C-X-C motif) ligand 9 Mus musculus 17-20 28245402-10 2017 CONCLUSION: Ac-YVAD-CMK can improve aGVHD by inhibiting Caspase 1 and reducing the release of some inflammatory cytokines, thereby alleviated the aGVHD pathological damage. ac-yvad 12-19 chemokine (C-X-C motif) ligand 9 Mus musculus 20-23 28078039-11 2016 The inhibitors of NLRP3 (Glyburide) and caspase-1 (AC-YVAD-CMK) alone or in combination were used to pre-treat the hepatic cells, which revealed that the pyroptosis rate was decreased and the cell damage alleviated. ac-yvad 51-58 chemokine (C-X-C motif) ligand 9 Mus musculus 59-62 23011098-6 2013 Furthermore, treatment of cells with the caspase-1 inhibitor Ac-YVAD-CMK dramatically decreased the percentage of pyroptosis. ac-yvad 61-68 chemokine (C-X-C motif) ligand 9 Mus musculus 69-72 27053298-0 2016 The caspase-1 inhibitor AC-YVAD-CMK attenuates acute gastric injury in mice: involvement of silencing NLRP3 inflammasome activities. ac-yvad 24-31 chemokine (C-X-C motif) ligand 9 Mus musculus 32-35 27053298-3 2016 Survival rates and histological evidence of gastric injury of mice pretreated with AC-YVAD-CMK or omeprazole, and exposed to cold-restraint stress, improved significantly relative to the vehicle group. ac-yvad 83-90 chemokine (C-X-C motif) ligand 9 Mus musculus 91-94 27053298-4 2016 The increased levels of tumour necrosis factor-alpha, interleukin (IL)-1beta, IL-6, and IL-18 following cold-stress injury were decreased by AC-YVAD-CMK, but not omeprazole, pretreatment. ac-yvad 141-148 chemokine (C-X-C motif) ligand 9 Mus musculus 149-152 27053298-5 2016 The increased expression of CD68 in gastric tissues was inhibited significantly by AC-YVAD-CMK pretreatment. ac-yvad 83-90 chemokine (C-X-C motif) ligand 9 Mus musculus 91-94 27053298-7 2016 AC-YVAD-CMK pretreatment significantly inhibited cold-restraint stress-induced increases in the expression of phosphorylated IkappaB-alpha and P38. ac-yvad 0-7 chemokine (C-X-C motif) ligand 9 Mus musculus 8-11 27053298-8 2016 General anatomy and histological results showed the protective effect of AC-YVAD-CMK on ethanol-induced acute gastric injury. ac-yvad 73-80 chemokine (C-X-C motif) ligand 9 Mus musculus 81-84 27053298-9 2016 Overall, our results showed that the caspase-1 inhibitor AC-YVAD-CMK protected against acute gastric injury in mice by affecting the NLRP3 inflammasome and attenuating inflammatory processes and apoptosis. ac-yvad 57-64 chemokine (C-X-C motif) ligand 9 Mus musculus 65-68 26415803-11 2015 The specific caspase-1 inhibitor Ac-YVAD-CMK inhibited the activation of caspase-1 and pyroptotic cell death. ac-yvad 33-40 chemokine (C-X-C motif) ligand 9 Mus musculus 41-44 26415803-12 2015 Ac-YVAD-CMK also reduced the lung injury, pulmonary edema and total protein in bronchoalveolar lavage fluid (BALF). ac-yvad 0-7 chemokine (C-X-C motif) ligand 9 Mus musculus 8-11 26415803-13 2015 In addition, Ac-YVAD-CMK significantly inhibited interleukin-alpha2 (IL-1alpha2) release both in serum and BALF and reduced the levels of IL-18, tumor necrosis factor-alpha+- (TNF-alpha+-), High Mobility Group Box 1 (HMGB1) in BALF during LPS-induced ALI/ARDS. ac-yvad 13-20 chemokine (C-X-C motif) ligand 9 Mus musculus 21-24 26415803-14 2015 CONCLUSIONS: This study reported AM pyroptosis during LPS-induced ALI/ARDS in mice and has demonstrated that Ac-YVAD-CMK can prevent AM-induced pyroptosis and lung injury. ac-yvad 109-116 chemokine (C-X-C motif) ligand 9 Mus musculus 117-120 24279434-8 2014 Pretreatment with the NLRP3 inflammasome inhibitor Ac-YVAD-CMK significantly abrogated the depressive-like behaviors induced by lipopolysaccharide. ac-yvad 51-58 chemokine (C-X-C motif) ligand 9 Mus musculus 59-62 21677131-6 2011 This was further substantiated by the use of a specific caspase-1 inhibitor, Ac-YVAD-CMK. ac-yvad 77-84 chemokine (C-X-C motif) ligand 9 Mus musculus 85-88 21921832-8 2012 Lastly, the functional significance of inflammasome activation following burn injury was tested in mice treated with the specific caspase-1 inhibitor, AC-YVAD-CMK. ac-yvad 151-158 chemokine (C-X-C motif) ligand 9 Mus musculus 159-162 21921832-15 2012 Surprisingly, we found that blocking caspase-1 activation with AC-YVAD-CMK in vivo caused significantly higher mortality in burn-injured mice (P < 0.01). ac-yvad 63-70 chemokine (C-X-C motif) ligand 9 Mus musculus 71-74 21677131-7 2011 Wild-type mice treated with Ac-YVAD-CMK (10 mg/kg s.c. twice daily, initiated at time of CLP) did not have impaired clearance of a Pseudomonas challenge compared with that of sham mice and had significantly improved bacterial clearance compared with that of untreated CLP mice. ac-yvad 28-35 chemokine (C-X-C motif) ligand 9 Mus musculus 36-39 16225757-2 2005 METHODS: Mouse models of ischemic ARF were treated with the specific ICE inhibitor AC-YVAD-CMK. ac-yvad 83-90 chemokine (C-X-C motif) ligand 9 Mus musculus 91-94 20823759-8 2010 Caspase-1 was blocked using the selective inhibitors Ac-YVAD-CMK and VRTXSD727. ac-yvad 53-60 chemokine (C-X-C motif) ligand 9 Mus musculus 61-64 20823759-12 2010 Pretreatment with Ac-YVAD-CMK significantly reduced mechanical allodynia and thermal hyperalgesia. ac-yvad 18-25 chemokine (C-X-C motif) ligand 9 Mus musculus 26-29 20596246-0 2010 Ac-YVAD-CMK Decreases Blood-Brain Barrier Degradation by Inhibiting Caspase-1 Activation of Interleukin-1beta in Intracerebral Hemorrhage Mouse Model. ac-yvad 0-7 chemokine (C-X-C motif) ligand 9 Mus musculus 8-11 20596246-3 2010 In this study, we tested the neuroprotective effect of Ac-YVAD-CMK, a known selective caspase-1 inhibitor, in a mouse model of intracerebral hemorrhage (ICH). ac-yvad 55-62 chemokine (C-X-C motif) ligand 9 Mus musculus 63-66 20596246-5 2010 Ac-YVAD-CMK or vehicle was administered into the left lateral ventricle 20 min before ICH modeling. ac-yvad 0-7 chemokine (C-X-C motif) ligand 9 Mus musculus 8-11 20596246-8 2010 At 24 h after ICH, Ac-YVAD-CMK treatment significantly reduced brain edema and improved neurological functions. ac-yvad 19-26 chemokine (C-X-C motif) ligand 9 Mus musculus 27-30 20596246-10 2010 We conclude that Ac-YVAD-CMK protects the brain against ICH-induced injury, and the neuroprotective effect may result from anti-inflammation-induced blood-brain barrier protection. ac-yvad 17-24 chemokine (C-X-C motif) ligand 9 Mus musculus 25-28 19875734-1 2009 BACKGROUND AND PURPOSE: We examined the effects of a caspase-1 inhibitor, N-Ac-Tyr-Val-Ala-Asp-chloromethyl ketone (Ac-YVAD-CMK), on neurogenic pulmonary edema in the endovascular perforation model of subarachnoid hemorrhage (SAH) in mice. ac-yvad 116-123 chemokine (C-X-C motif) ligand 9 Mus musculus 124-127 19875734-5 2009 RESULTS: Ten- but not 6-mg/kg of Ac-YVAD-CMK significantly inhibited a post-SAH increase in the activation of interleukin-1beta and caspase-3 and the number of terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling-positive pulmonary endothelial cells, preventing neurogenic pulmonary edema. ac-yvad 33-40 chemokine (C-X-C motif) ligand 9 Mus musculus 41-44 19875734-8 2009 CONCLUSIONS: We report for the first time that Ac-YVAD-CMK prevents lung cell apoptosis and neurogenic pulmonary edema after SAH in mice. ac-yvad 47-54 chemokine (C-X-C motif) ligand 9 Mus musculus 55-58 19461019-7 2009 Although both dosages of Ac-YVAD-CMK attenuated the mature IL-1beta induction, only high-dose treatment group significantly inhibited the phosphorylation of JNK, MMP-9 induction, and ZO-1 degradation. ac-yvad 25-32 chemokine (C-X-C motif) ligand 9 Mus musculus 33-36 19461019-9 2009 The neurovascular protection of Ac-YVAD-CMK may be provided by the inhibition of JNK-mediated MMP-9 induction and the consequent preservation of tight junction protein ZO-1. ac-yvad 32-39 chemokine (C-X-C motif) ligand 9 Mus musculus 40-43 16225757-3 2005 A renal function assay and renal morphological studies were employed to estimate the renal protective effect of AC-YVAD-CMK. ac-yvad 112-119 chemokine (C-X-C motif) ligand 9 Mus musculus 120-123 16225757-11 2005 AC-YVAD-CMK therapy alleviated the clinical features of ARF, and increased the survival rate (P<0.01). ac-yvad 0-7 chemokine (C-X-C motif) ligand 9 Mus musculus 8-11 16225757-12 2005 Furthermore, AC-YVAD-CMK therapy also decreased ICE activity, mature IL-18 protein expression, and IFN-gamma mRNA expression in renal tissue (P<0.05). ac-yvad 13-20 chemokine (C-X-C motif) ligand 9 Mus musculus 21-24 16225757-13 2005 CONCLUSION: The selective ICE inhibitor AC-YVAD-CMK can effectively protect the kidney from acute ischemic lesions. ac-yvad 40-47 chemokine (C-X-C motif) ligand 9 Mus musculus 48-51 34222479-0 2021 Caspase-1-Inhibitor AC-YVAD-CMK Inhibits Pyroptosis and Ameliorates Acute Kidney Injury in a Model of Sepsis. ac-yvad 20-27 chemokine (C-X-C motif) ligand 9 Mus musculus 28-31 9373772-7 1997 Contrary to expectations, the peptide aldehydes listed above and Ac-YVAD-Cmk, known as highly specific ICE inhibitors, did not inhibit the apoptosis of these cell types. ac-yvad 65-72 chemokine (C-X-C motif) ligand 9 Mus musculus 73-76 8521409-6 1995 The apoptosis induced by cisplatin treatment or murine ICE overexpression can be suppressed by the tetrapeptide ICE inhibitor Ac-YVAD-CMK or the apoptosis inhibitors bcl-2 or bcl-2-related bcl-XL gene. ac-yvad 126-133 chemokine (C-X-C motif) ligand 9 Mus musculus 134-137 34222479-1 2021 Objective: To observe the protective effect of AC-YVAD-CMK on sepsis-induced acute kidney injury in mice and to explore its possible mechanisms primarily. ac-yvad 47-54 chemokine (C-X-C motif) ligand 9 Mus musculus 55-58 34222479-2 2021 Methods: Eighteen male C57BL/6 mice were randomly divided into sham-operated group (Control), cecal ligation and puncture group (CLP), and CLP model treated with AC-YVAD-CMK group (AC-YVAD-CMK) (n = 6 in each group). ac-yvad 162-169 chemokine (C-X-C motif) ligand 9 Mus musculus 170-173 34222479-12 2021 In addition, AC-YVAD-CMK treatment significantly reduced the expression of GSDMD in renal tissues compared to those observed in controls (P < 0.05). ac-yvad 13-20 chemokine (C-X-C motif) ligand 9 Mus musculus 21-24 33647825-2 2021 Therefore, we aimed to elucidate the mechanism of Caspase-1 in in murine models of aGVHD through specific inhibition of its activity with the decoy peptide Ac-YVAD-CMK. ac-yvad 156-163 chemokine (C-X-C motif) ligand 9 Mus musculus 164-167 33647825-7 2021 Thus, we demonstrate that inhibition of Caspase-1 by Ac-YVAD-CMK mitigates murine aGVHD by regulating Th1/Th17/Treg balance and attenuating its characteristic proinflammatory state. ac-yvad 53-60 chemokine (C-X-C motif) ligand 9 Mus musculus 61-64 33493800-6 2021 The blockade of inflammasome activation by the inhibitor Ac-YVAD-CMK abrogated AIM2-mediated M1 polarization and the inhibition of tumor cell growth. ac-yvad 57-64 chemokine (C-X-C motif) ligand 9 Mus musculus 65-68 33509083-6 2021 APP/PS1 mice and Abeta1-42-induced hippocampal neurones were treated with AC-YVAD-CMK (caspase-1 inhibitor). ac-yvad 74-81 chemokine (C-X-C motif) ligand 9 Mus musculus 82-85 33509083-11 2021 RESULTS: AC-YVAD-CMK treatment improved spatial learning and memory ability and reduced senile plaque deposition of APP/PS1 mice. ac-yvad 9-16 chemokine (C-X-C motif) ligand 9 Mus musculus 17-20 33509083-12 2021 Moreover, AC-YVAD-CMK promoted membrane transport of GluA1 in APP/PS1 mice. ac-yvad 10-17 chemokine (C-X-C motif) ligand 9 Mus musculus 18-21 32201254-10 2020 AIM2 knockout (KO) and Ac-YVAD-CMK-induced caspase-1 inhibition in mice significantly improved cognitive function and reversed brain volume in the hippocampus relative to those in stroke mice. ac-yvad 23-30 chemokine (C-X-C motif) ligand 9 Mus musculus 31-34